{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:05:03Z","timestamp":1792695903479,"version":"4.5.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009448","name":"Universit\u00e0 degli Studi della Campania Luigi Vanvitelli","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009448","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Opinion statement<\/jats:title><jats:p>About 70\u201380% of early breast cancer (BC) patients receive adjuvant endocrine therapy (ET) for at least 5 years. ET includes in the majority of cases the use of aromatase inhibitors, as upfront or switch strategy, that lead to impaired bone health. Given the high incidence and also the high prevalence of BC, cancer treatment\u2013induced bone loss (CTIBL) represents the most common long-term adverse event experimented by patients with hormone receptor positive tumours. CTIBL is responsible for osteoporosis occurrence and, as a consequence, fragility fractures that may negatively affect quality of life and survival expectancy. As recommended by main international guidelines, BC women on aromatase inhibitors should be carefully assessed for their fracture risk at baseline and periodically reassessed during adjuvant ET in order to early detect significant worsening in terms of bone health. Antiresorptive agents, together with adequate intake of calcium and vitamin D, should be administered in BC patients during all course of ET, especially in those at high risk of osteoporotic fractures, as calculated by tools available for clinicians. Bisphosphonates, such as zoledronate or pamidronate, and anti-RANKL antibody, denosumab, are the two classes of antiresorptive drugs used in clinical practice with similar efficacy in preventing bone loss induced by aromatase inhibitor therapy. The choice between them, in the absence of direct comparison, should be based on patients\u2019 preference and compliance; the different safety profile is mainly related to the route of administration, although both types of drugs are manageable with due care, since most of the adverse events are predictable and preventable. Despite advances in management of CTIBL, several issues such as the optimal time of starting antiresorptive agents and the duration of treatment remain unanswered. Future clinical trials as well as increased awareness of bone health are needed to improve prevention, assessment and treatment of CTIBL in these long-term survivor patients.<\/jats:p>","DOI":"10.1007\/s11864-021-00835-2","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T16:03:47Z","timestamp":1618589027000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Cancer Treatment\u2013Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy"],"prefix":"10.1007","volume":"22","author":[{"given":"Anna","family":"Diana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio Francesco","family":"Giunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisena","family":"Franzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Pio","family":"Guerrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Di Lauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Orditura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,16]]},"reference":[{"issue":"6","key":"835_CR1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3322\/caac.21583","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438\u201351. https:\/\/doi.org\/10.3322\/caac.21583.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"835_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.4103\/2278-330X.130445","volume":"3","author":"S Agrawal","year":"2014","unstructured":"Agrawal S. Late effects of cancer treatment in breast cancer survivors. South Asian J Cancer. 2014;3(2):112\u20135. https:\/\/doi.org\/10.4103\/2278-330X.130445.","journal-title":"South Asian J Cancer"},{"key":"835_CR3","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/bonekey.2015.60","volume":"4","author":"P Hadji","year":"2015","unstructured":"Hadji P. Cancer treatment-induced bone loss in women with breast cancer. Bonekey Rep. 2015;4:692. https:\/\/doi.org\/10.1038\/bonekey.2015.60.","journal-title":"Bonekey Rep"},{"issue":"3","key":"835_CR4","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1158\/1078-0432.CCR-10-1595","volume":"17","author":"BJ Edwards","year":"2011","unstructured":"Edwards BJ, Raisch DW, Shankaran V, et al. Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clin Cancer Res. 2011;17(3):560\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1595.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"835_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1152\/physiol.00061.2014","volume":"31","author":"JA Siddiqui","year":"2016","unstructured":"Siddiqui JA, Partridge NC. Physiological bone remodeling: systemic regulation and growth factor involvement. Physiology (Bethesda). 2016;31(3):233\u201345. https:\/\/doi.org\/10.1152\/physiol.00061.2014.","journal-title":"Physiology (Bethesda)"},{"key":"835_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000351896","volume":"18","author":"W Xiao","year":"2016","unstructured":"Xiao W, Li S, Pacios S, Wang Y, Graves DT. Bone remodeling under pathological conditions. Front Oral Biol. 2016;18:17\u201327. https:\/\/doi.org\/10.1159\/000351896.","journal-title":"Front Oral Biol"},{"issue":"12","key":"835_CR7","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1177\/0022034510377791","volume":"89","author":"AL Boskey","year":"2010","unstructured":"Boskey AL, Coleman R. Aging and bone. J Dent Res. 2010;89(12):1333\u201348. https:\/\/doi.org\/10.1177\/0022034510377791.","journal-title":"J Dent Res"},{"issue":"2","key":"835_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jocd.2014.08.001","volume":"19","author":"J Lu","year":"2016","unstructured":"Lu J, Shin Y, Yen MS, Sun SS. Peak bone mass and patterns of change in total bone mineral density and bone mineral contents from childhood into young adulthood. J Clin Densitom. 2016;19(2):180\u201391. https:\/\/doi.org\/10.1016\/j.jocd.2014.08.001.","journal-title":"J Clin Densitom"},{"key":"835_CR9","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00198-015-3440-3","volume":"27","author":"CM Weaver","year":"2016","unstructured":"Weaver CM, Gordon CM, Janz KF, et al. The National Osteoporosis Foundation\u2019s position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. Osteoporos Int. 2016;27:1281\u2013386. https:\/\/doi.org\/10.1007\/s00198-015-3440-3.","journal-title":"Osteoporos Int"},{"issue":"1","key":"835_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/toxsci\/55.1.171","volume":"55","author":"EJ O'Flaherty","year":"2000","unstructured":"O'Flaherty EJ. Modeling normal aging bone loss, with consideration of bone loss in osteoporosis. Toxicol Sci. 2000;55(1):171\u201388. https:\/\/doi.org\/10.1093\/toxsci\/55.1.171.","journal-title":"Toxicol Sci"},{"issue":"4","key":"835_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa022464","volume":"349","author":"HG Ahlborg","year":"2003","unstructured":"Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK. Bone loss and bone size after menopause. N Engl J Med. 2003;349(4):327\u201334. https:\/\/doi.org\/10.1056\/NEJMoa022464.","journal-title":"N Engl J Med"},{"issue":"1","key":"835_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1210\/edrv.23.1.0456","volume":"23","author":"J Pfeilschifter","year":"2002","unstructured":"Pfeilschifter J, K\u00f6ditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev. 2002;23(1):90\u2013119. https:\/\/doi.org\/10.1210\/edrv.23.1.0456.","journal-title":"Endocr Rev"},{"issue":"8","key":"835_CR13","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/jbmr.5650090821","volume":"9","author":"WR McKane","year":"1994","unstructured":"McKane WR, Khosla S, Peterson JM, Egan K, Riggs BL. Circulating levels of cytokines that modulate bone resorption: effects of age and menopause in women. J Bone Miner Res. 1994;9(8):1313\u20138. https:\/\/doi.org\/10.1002\/jbmr.5650090821.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"835_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.11613\/bm.2013.007","volume":"23","author":"J Zupan","year":"2013","unstructured":"Zupan J, Jeras M, Marc J. Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclasts. Biochem Med (Zagreb). 2013;23(1):43\u201363. https:\/\/doi.org\/10.11613\/bm.2013.007.","journal-title":"Biochem Med (Zagreb)"},{"issue":"2","key":"835_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/s8756-3282(02)00953-5","volume":"32","author":"S Bord","year":"2003","unstructured":"Bord S, Ireland DC, Beavan SR, Compston JE. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone. 2003;32(2):136\u201341. https:\/\/doi.org\/10.1016\/s8756-3282(02)00953-5.","journal-title":"Bone"},{"issue":"11","key":"835_CR16","doi-asserted-by":"publisher","first-page":"E3094","DOI":"10.3390\/cancers12113094","volume":"12","author":"CL Shapiro","year":"2020","unstructured":"\u2022Shapiro CL. Osteoporosis: a long-term and late-effect of breast cancer treatments. Cancers (Basel). 2020;12(11):E3094. https:\/\/doi.org\/10.3390\/cancers12113094. Concise review about osteoporosis as a consequence of breast cancer treatments.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"835_CR17","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s10549-010-0899-7","volume":"123","author":"DA Cameron","year":"2010","unstructured":"Cameron DA, Douglas S, Brown JE, Anderson RA. Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency? Breast Cancer Res Treat. 2010;123(3):805\u201314. https:\/\/doi.org\/10.1007\/s10549-010-0899-7.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"835_CR18","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"\u2022Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194\u2013220. https:\/\/doi.org\/10.1093\/annonc\/mdz173. European guidelines for early breast cancer treatment.","journal-title":"Ann Oncol"},{"issue":"4","key":"835_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.4184\/asj.2016.10.4.787","volume":"10","author":"KC An","year":"2016","unstructured":"An KC. Selective estrogen receptor modulators. Asian Spine J. 2016;10(4):787\u201391. https:\/\/doi.org\/10.4184\/asj.2016.10.4.787.","journal-title":"Asian Spine J"},{"issue":"4","key":"835_CR20","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/1097-0142","volume":"53","author":"A Gotfredsen","year":"1984","unstructured":"Gotfredsen A, Christiansen C, Palshof T. The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer. 1984;53(4):853\u20137. https:\/\/doi.org\/10.1002\/1097-0142.","journal-title":"Cancer"},{"issue":"13","key":"835_CR21","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1056\/NEJM199203263261302","volume":"326","author":"RR Love","year":"1992","unstructured":"Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326(13):852\u20136. https:\/\/doi.org\/10.1056\/NEJM199203263261302.","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"835_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.steroids.2011.10.013","volume":"77","author":"C Stocco","year":"2012","unstructured":"Stocco C. Tissue physiology and pathology of aromatase. Steroids. 2012;77(1\u20132):27\u201335. https:\/\/doi.org\/10.1016\/j.steroids.2011.10.013.","journal-title":"Steroids"},{"issue":"4","key":"835_CR23","doi-asserted-by":"publisher","first-page":"R52","DOI":"10.1186\/bcr1757","volume":"9","author":"PE Goss","year":"2007","unstructured":"Goss PE, Hadji P, Subar M, Abreu P, Thomsen T, Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res. 2007;9(4):R52. https:\/\/doi.org\/10.1186\/bcr1757.","journal-title":"Breast Cancer Res"},{"key":"835_CR24","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1210\/me.2014-1147","volume":"28","author":"M Liu","year":"2014","unstructured":"Liu M, Goss PE, Ingle JN, et al. Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics. Mol Endocrinol. 2014;28:1740\u201351. https:\/\/doi.org\/10.1210\/me.2014-1147.","journal-title":"Mol Endocrinol"},{"issue":"9","key":"835_CR25","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","volume":"20","author":"M Rabaglio","year":"2009","unstructured":"Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thurlimann B, et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1\u201398 trial. Ann Oncol. 2009;20(9):1489\u201398. https:\/\/doi.org\/10.1093\/annonc\/mdp033.","journal-title":"Ann Oncol"},{"issue":"19","key":"835_CR26","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa032312","volume":"349","author":"PE Goss","year":"2003","unstructured":"Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793\u2013802. https:\/\/doi.org\/10.1056\/NEJMoa032312.","journal-title":"N Engl J Med"},{"issue":"1","key":"835_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","volume":"9","author":"JF Forbes","year":"2008","unstructured":"Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Arimidex, tamoxifen, alone or in combination (ATAC) Trialists\u2019 group effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45\u201353. https:\/\/doi.org\/10.1016\/S1470-2045(07)70385-6.","journal-title":"Lancet Oncol"},{"issue":"4","key":"835_CR28","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/annonc\/mdq541","volume":"22","author":"R Eastell","year":"2011","unstructured":"Eastell R, Adams J, Clack G, Howell A, Cuzick J, Mackey J, et al. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann Oncol. 2011;22(4):857\u201362. https:\/\/doi.org\/10.1093\/annonc\/mdq541.","journal-title":"Ann Oncol"},{"issue":"11","key":"835_CR29","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"RC Coombes","year":"2004","unstructured":"Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. Intergroup Exemestane study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081\u201392. https:\/\/doi.org\/10.1056\/NEJMoa040331.","journal-title":"N Engl J Med"},{"key":"835_CR30","doi-asserted-by":"publisher","unstructured":"Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, et al. Intergroup Exemestane study group. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the intergroup Exemestane study (IES): a randomised controlled study. Lancet Oncol. 2007;8(2):119\u201327. https:\/\/doi.org\/10.1016\/S1470-2045(07)70003-7.","DOI":"10.1016\/S1470-2045(07)70003-7"},{"issue":"1","key":"835_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-010-1121-7","volume":"124","author":"RE Coleman","year":"2010","unstructured":"Coleman RE, Banks LM, Girgis SI, Vrdoljak E, Fox J, Cawthorn SJ, et al. Reversal of skeletal effects of endocrine treatments in the intergroup Exemestane study. Breast Cancer Res Treat. 2010;124(1):153\u201361. https:\/\/doi.org\/10.1007\/s10549-010-1121-7.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"835_CR32","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.2016.69.2871","volume":"35","author":"I Smith","year":"2017","unstructured":"Smith I, Yardley D, Burris HA, De Boer R, Amadori D, McIntyre K, et al. Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor\u2013positive, node-positive early breast cancer: final results of the randomized phase III Femara versus Anastrozole clinical evaluation (FACE) trial. J Clin Oncol. 2017;35(10):1041\u20138. https:\/\/doi.org\/10.1200\/JCO.2016.69.2871.","journal-title":"J Clin Oncol"},{"issue":"11","key":"835_CR33","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1200\/JCO.2012.44.7805","volume":"31","author":"PE Goss","year":"2013","unstructured":"Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27-a randomized controlled phase III trial. J Clin Oncol. 2013;31(11):1398\u2013404. https:\/\/doi.org\/10.1200\/JCO.2012.44.7805.","journal-title":"J Clin Oncol"},{"key":"835_CR34","doi-asserted-by":"publisher","unstructured":"\u2022Pedersini R, Monteverdi S, Mazziotti G, Amoroso V, Roca E, Maffezzoni F, et al. Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: a cross-sectional study. Bone. 2017:147\u201352. https:\/\/doi.org\/10.1016\/j.bone.2017.01.013. Study exploring prevalence and determinants of vertebral fractures before and during aromatase inhibitor therapy in breast cancer patients.","DOI":"10.1016\/j.bone.2017.01.013"},{"issue":"9","key":"835_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.11080","volume":"2","author":"R Pedersini","year":"2019","unstructured":"Pedersini R, Amoroso V, Maffezzoni F, et al. Association of fat Body Mass with Vertebral Fractures in postmenopausal women with early breast Cancer undergoing adjuvant aromatase inhibitor therapy. JAMA Netw Open. 2019;2(9):e1911080. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.11080.","journal-title":"JAMA Netw Open"},{"key":"835_CR36","doi-asserted-by":"publisher","unstructured":"\u2022Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, et al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. J Bone Oncol. 2017 Mar 23;7(1):\u201312. https:\/\/doi.org\/10.1016\/j.jbo.2017.03.001. Position paper about management of aromatase inhibitor-associated bone loss.","DOI":"10.1016\/j.jbo.2017.03.001"},{"key":"835_CR37","doi-asserted-by":"publisher","unstructured":"\u2022Shapiro CL, Van Poznak C, Lacchetti C, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol. 2019;37(31):2916\u201346. https:\/\/doi.org\/10.1200\/JCO.19.01696. Guidelines on proper management of osteoporosis in adult cancer survivors.","DOI":"10.1200\/JCO.19.01696"},{"issue":"Suppl3","key":"835_CR38","doi-asserted-by":"publisher","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","volume":"25","author":"R Coleman","year":"2014","unstructured":"Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J, On behalf of the ESMO guidelines Working Group. Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2014;25(Suppl3):iii124\u201337. https:\/\/doi.org\/10.1093\/annonc\/mdu103.","journal-title":"Ann Oncol"},{"key":"835_CR39","first-page":"897","volume":"63","author":"J South-Paul","year":"2001","unstructured":"South-Paul J. Osteoporosis, part I: evaluation and assessment. Am Fam Physician. 2001;63:897\u2013904.","journal-title":"Am Fam Physician"},{"issue":"982","key":"835_CR40","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1136\/pgmj.2007.057505","volume":"83","author":"GM Blake","year":"2007","unstructured":"Blake GM, Fogelman I. The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad Med J. 2007;83(982):509\u201317. https:\/\/doi.org\/10.1136\/pgmj.2007.057505.","journal-title":"Postgrad Med J"},{"issue":"3","key":"835_CR41","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s001980050281","volume":"11","author":"JA Kanis","year":"2000","unstructured":"Kanis JA, Gl\u00fcer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, international Osteoporosis Foundation. Osteoporos Int. 2000;11(3):192\u2013202. https:\/\/doi.org\/10.1007\/s001980050281.","journal-title":"Osteoporos Int"},{"issue":"7","key":"835_CR42","doi-asserted-by":"publisher","first-page":"875","DOI":"10.6004\/jnccn.2016.0092","volume":"14","author":"J Charlson","year":"2016","unstructured":"Charlson J, Smith EC, Smallwood AJ, Laud PW, Neuner JM. Bone mineral density testing disparities among patients with breast cancer prescribed aromatase inhibitors. J Natl Compr Cancer Netw. 2016;14(7):875\u201380. https:\/\/doi.org\/10.6004\/jnccn.2016.0092.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"5","key":"835_CR43","doi-asserted-by":"publisher","first-page":"e505","DOI":"10.1200\/JOP.2016.018341","volume":"13","author":"J Stratton","year":"2017","unstructured":"\u2022Stratton J, Hu X, Soulos PR, Davidoff AJ, Pusztai L, Gross CP, et al. Bone density screening in postmenopausal women with early-stage breast cancer treated with aromatase inhibitors. J Oncol Pract. 2017;13(5):e505\u201315. https:\/\/doi.org\/10.1200\/JOP.2016.018341. Large retrospective analysis highlighting scares adherence in older patients to bone density screening.","journal-title":"J Oncol Pract"},{"issue":"10","key":"835_CR44","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/jbmr.2531","volume":"30","author":"JA Kanis","year":"2015","unstructured":"Kanis JA, McCloskey EV, Harvey NC, Johansson H, Leslie WD. Intervention thresholds and the diagnosis of osteoporosis. J Bone Miner Res. 2015;30(10):1747\u201353. https:\/\/doi.org\/10.1002\/jbmr.2531.","journal-title":"J Bone Miner Res"},{"key":"835_CR45","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s11657-013-0166-8","volume":"9","author":"JA Kanis","year":"2014","unstructured":"Kanis JA, Johansson H, Oden A, Cooper C, EV MC, the Epidemiology and Quality of Life Working Group of IOF. Worldwide uptake of FRAX. Arch Osteoporos. 2014;9:166. https:\/\/doi.org\/10.1007\/s11657-013-0166-8.","journal-title":"Arch Osteoporos"},{"key":"835_CR46","unstructured":"https:\/\/www.sheffield.ac.uk\/FRAX (visited on 21st October 2020)."},{"issue":"8","key":"835_CR47","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/jbmr.3726","volume":"34","author":"WD Leslie","year":"2019","unstructured":"\u2022Leslie WD, Morin SN, Lix LM, Niraula S, EV MC, Johansson H, et al. Performance of FRAX in women with breast Cancer initiating aromatase inhibitor therapy: a registry-based cohort study. J Bone Miner Res. 2019;34(8):1428\u201335. https:\/\/doi.org\/10.1002\/jbmr.3726. Study evaluating a specific tool in breast cancer patients on aromatase inhibitor therapy.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"835_CR48","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/jbmr.2176","volume":"29","author":"BC Silva","year":"2014","unstructured":"Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N, et al. Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res. 2014;29(3):518\u201330. https:\/\/doi.org\/10.1002\/jbmr.2176.","journal-title":"J Bone Miner Res"},{"key":"835_CR49","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1002\/jbmr.499","volume":"26","author":"D Hans","year":"2011","unstructured":"Hans D, Goertzen AL, Krieg MA, Leslie WD. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res. 2011;26:2762\u20139. https:\/\/doi.org\/10.1002\/jbmr.499.","journal-title":"J Bone Miner Res"},{"key":"835_CR50","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40364-017-0097-4","volume":"5","author":"TR Kuo","year":"2017","unstructured":"Kuo TR, Chen CH. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomark Res. 2017;5:18. https:\/\/doi.org\/10.1186\/s40364-017-0097-4.","journal-title":"Biomark Res"},{"issue":"3","key":"835_CR51","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.breast.2009.03.003","volume":"18","author":"P Hadji","year":"2009","unstructured":"Hadji P, Ziller M, Kieback DG, Menschik T, Kalder M, Kuck J, et al. The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the tamoxifen Exemestane adjuvant multicentre (TEAM) trial. Breast. 2009;18(3):159\u201364. https:\/\/doi.org\/10.1016\/j.breast.2009.03.003.","journal-title":"Breast"},{"issue":"3","key":"835_CR52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.afos.2019.09.005","volume":"5","author":"R Coronado-Zarco","year":"2019","unstructured":"Coronado-Zarco R, Olascoaga-G\u00f3mez de Le\u00f3n A, Garc\u00eda-Lara A, Quinza\u00f1os-Fresnedo J, Nava-Bringas TI, Mac\u00edas-Hern\u00e1ndez SI. Nonpharmacological interventions for osteoporosis treatment: systematic review of clinical practice guidelines. Osteoporos Sarcopenia. 2019;5(3):69\u201377. https:\/\/doi.org\/10.1016\/j.afos.2019.09.005.","journal-title":"Osteoporos Sarcopenia"},{"issue":"7","key":"835_CR53","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1001\/archinte.161.7.983","volume":"161","author":"JA Baron","year":"2001","unstructured":"Baron JA, Farahmand BY, Weiderpass E, Micha\u00eblsson K, Alberts A, Persson I, et al. Cigarette smoking, alcohol consumption, and risk of hip fracture in women. Arch Intern Med. 2001;161(7):983\u20138. https:\/\/doi.org\/10.1001\/archinte.161.7.983.","journal-title":"Arch Intern Med"},{"issue":"5","key":"835_CR54","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.amjmed.2007.12.012","volume":"121","author":"KM Berg","year":"2008","unstructured":"Berg KM, Kunins HV, Jackson JL, Nahvi S, Chaudhry A, Harris KA Jr, et al. Association between alcohol consumption and both osteoporotic fracture and bone density. Am J Med. 2008;121(5):406\u201318. https:\/\/doi.org\/10.1016\/j.amjmed.2007.12.012.","journal-title":"Am J Med"},{"issue":"1","key":"835_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4082\/kjfm.2014.35.1.1","volume":"35","author":"SY Kim","year":"2014","unstructured":"Kim SY. Coffee consumption and risk of osteoporosis. Korean J Fam Med. 2014;35(1):1. https:\/\/doi.org\/10.4082\/kjfm.2014.35.1.1.","journal-title":"Korean J Fam Med"},{"issue":"9","key":"835_CR56","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/s0278-6915(02)00094-7","volume":"40","author":"RP Heaney","year":"2002","unstructured":"Heaney RP. Effects of caffeine on bone and the calcium economy. Food Chem Toxicol. 2002;40(9):1263\u201370. https:\/\/doi.org\/10.1016\/s0278-6915(02)00094-7.","journal-title":"Food Chem Toxicol"},{"key":"835_CR57","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1741-7015-8-47","volume":"8","author":"R Nikander","year":"2010","unstructured":"Nikander R, Siev\u00e4nen H, Heinonen A, Daly RM, Uusi-Rasi K, Kannus P. Targeted exercise against osteoporosis: a systematic review and meta-analysis for optimising bone strength throughout life. BMC Med. 2010;8:47. https:\/\/doi.org\/10.1186\/1741-7015-8-47.","journal-title":"BMC Med"},{"issue":"1","key":"835_CR58","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1210\/jc.2010-2704","volume":"96","author":"AC Ross","year":"2011","unstructured":"Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53\u20138. https:\/\/doi.org\/10.1210\/jc.2010-2704.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"835_CR59","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jare.2014.01.011","volume":"6","author":"WZ Mostafa","year":"2015","unstructured":"Mostafa WZ, Hegazy RA. Vitamin D and the skin: focus on a complex relationship: a review. J Adv Res. 2015;6(6):793\u2013804. https:\/\/doi.org\/10.1016\/j.jare.2014.01.011.","journal-title":"J Adv Res"},{"issue":"4","key":"835_CR60","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/nbu.12108","volume":"39","author":"A Spiro","year":"2014","unstructured":"Spiro A, Buttriss JL. Vitamin D: An overview of vitamin D status and intake in Europe. Nutr Bull. 2014;39(4):322\u201350. https:\/\/doi.org\/10.1111\/nbu.12108.","journal-title":"Nutr Bull"},{"issue":"9","key":"835_CR61","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.4158\/EP161435.ESGL","volume":"22","author":"PM Camacho","year":"2016","unstructured":"Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016--executive summary. Endocr Pract. 2016;22(9):1111\u20138. https:\/\/doi.org\/10.4158\/EP161435.ESGL.","journal-title":"Endocr Pract"},{"key":"835_CR62","unstructured":"National Comprehensive Cancer Network. Guidelines for treatment of cancer by site: breast cancer v6; 2020. Retrieved November 10, 2020, from https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx#site."},{"key":"835_CR63","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.critrevonc.2013.07.002","volume":"88","author":"M Datta","year":"2013","unstructured":"Datta M, Schwartz GG. Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy. Crit Rev Oncol Hematol. 2013;88:613\u201324. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.07.002.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Suppl2","key":"835_CR64","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/jbmr.5650140212","volume":"14","author":"RG Russell","year":"1999","unstructured":"Russell RG, Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res. 1999;14(Suppl2):53\u201365. https:\/\/doi.org\/10.1002\/jbmr.5650140212.","journal-title":"J Bone Miner Res"},{"issue":"9","key":"835_CR65","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032\u201345. https:\/\/doi.org\/10.4065\/83.9.1032.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"835_CR66","doi-asserted-by":"publisher","first-page":"37","DOI":"10.11005\/jbm.2017.24.1.37","volume":"24","author":"JH Byun","year":"2017","unstructured":"Byun JH, Jang S, Lee S, et al. The efficacy of bisphosphonates for prevention of osteoporotic fracture: An update meta-analysis. J Bone Metab. 2017;24(1):37\u201349. https:\/\/doi.org\/10.11005\/jbm.2017.24.1.37.","journal-title":"J Bone Metab"},{"issue":"4","key":"835_CR67","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.semarthrit.2010.06.001","volume":"40","author":"JP Jansen","year":"2011","unstructured":"Jansen JP, Bergman GJ, Huels J, Olson M. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum. 2011;40(4):275\u201384.e1-2. https:\/\/doi.org\/10.1016\/j.semarthrit.2010.06.001.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"835_CR68","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/bjc.1997.105","volume":"75","author":"T Saarto","year":"1997","unstructured":"Saarto T, Blomqvist C, V\u00e4lim\u00e4ki M, M\u00e4kel\u00e4 P, Sarna S, Elomaa I. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer. 1997;75(4):602\u20135. https:\/\/doi.org\/10.1038\/bjc.1997.105.","journal-title":"Br J Cancer"},{"issue":"2","key":"835_CR69","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jbo.2012.06.002","volume":"1","author":"JE Lester","year":"2012","unstructured":"Lester JE, Dodwell D, Brown JE, Purohit OP, Gutcher SA, Ellis SP, et al. Prevention of anastrozole induced bone loss with monthly oral ibandronate: final 5 year results from the ARIBON trial. J Bone Oncol. 2012;1(2):57\u201362. https:\/\/doi.org\/10.1016\/j.jbo.2012.06.002.","journal-title":"J Bone Oncol"},{"issue":"6","key":"835_CR70","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","volume":"28","author":"C Van Poznak","year":"2010","unstructured":"Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol. 2010;28(6):967\u201375. https:\/\/doi.org\/10.1200\/JCO.2009.24.5902.","journal-title":"J Clin Oncol"},{"issue":"13","key":"835_CR71","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S1470-2045(14)71035-6","volume":"15","author":"I Sestak","year":"2014","unstructured":"Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, et al. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebocontrolled trial. Lancet Oncol. 2014;15(13):1460\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(14)71035-6.","journal-title":"Lancet Oncol"},{"issue":"9","key":"835_CR72","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","volume":"9","author":"M Gnant","year":"2008","unstructured":"Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, K\u00e4ssmann H, Moik M, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008;9(9):840\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(08)70204-3.","journal-title":"Lancet Oncol"},{"issue":"7","key":"835_CR73","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","volume":"25","author":"A Brufsky","year":"2007","unstructured":"Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25(7):829\u201336. https:\/\/doi.org\/10.1200\/JCO.2005.05.3744.","journal-title":"J Clin Oncol"},{"issue":"4","key":"835_CR74","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S1470-2045(14)70035-X","volume":"15","author":"PE Goss","year":"2014","unstructured":"Goss PE, Hershman DL, Cheung AM, Ingle JN, Khosla S, Stearns V, et al. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. Lancet Oncol. 2014;15(4):474\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(14)70035-X.","journal-title":"Lancet Oncol"},{"issue":"5","key":"835_CR75","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/cncr.26313","volume":"118","author":"AM Brufsky","year":"2012","unstructured":"Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer. 2012;118(5):1192\u2013201. https:\/\/doi.org\/10.1002\/cncr.26313.","journal-title":"Cancer"},{"key":"835_CR76","doi-asserted-by":"crossref","unstructured":"Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013;24(2):398\u2013405.","DOI":"10.1093\/annonc\/mds277"},{"issue":"1","key":"835_CR77","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.clbc.2011.08.002","volume":"12","author":"A Llombart","year":"2012","unstructured":"Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, et al. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in postmenopausal women with early breast Cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer. 2012;12(1):40\u20138. https:\/\/doi.org\/10.1016\/j.clbc.2011.08.002.","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"835_CR78","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bone.2010.10.161","volume":"48","author":"A Lipton","year":"2011","unstructured":"Lipton A, Goessl C. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone. 2011;48(1):96\u20139. https:\/\/doi.org\/10.1016\/j.bone.2010.10.161.","journal-title":"Bone"},{"issue":"16","key":"835_CR79","doi-asserted-by":"publisher","first-page":"6647","DOI":"10.18632\/oncotarget.2160","volume":"5","author":"A Schieferdecker","year":"2014","unstructured":"Schieferdecker A, Voigt M, Riecken K, et al. Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL. Oncotarget. 2014;5(16):6647\u201353. https:\/\/doi.org\/10.18632\/oncotarget.2160.","journal-title":"Oncotarget"},{"issue":"9992","key":"835_CR80","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, et al. Austrian breast and colorectal Cancer study group. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9992):433\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(15)60995-3.","journal-title":"Lancet"},{"key":"835_CR81","doi-asserted-by":"publisher","unstructured":"\u2022Perrone F, De Laurentiis M, De Placido S, Orditura M, Cinieri S, Riccardi F, et al. Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer:HOBOE phase 3 randomised trial. Eur J Cancer. 2019 Sep;118:178\u201386. https:\/\/doi.org\/10.1016\/j.ejca.2019.05.004. A randomized phase 3 trial showing a significant improvement in DFS by adding zoledronic acid to endocrine therapy in premenopausal patients with early breast cancer.","DOI":"10.1016\/j.ejca.2019.05.004"},{"issue":"10001","key":"835_CR82","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","volume":"386","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2015","unstructured":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386(10001):1353\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(15)60908-4.","journal-title":"Lancet"},{"issue":"1","key":"835_CR83","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","volume":"21","author":"R Coleman","year":"2020","unstructured":"\u2022Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(1):60\u201372. https:\/\/doi.org\/10.1016\/S1470-2045(19)30687-4. Multicenter randomized study evaluating the role of denosumab in adjuvant setting for all breast cancer molecular subgroups.","journal-title":"Lancet Oncol"},{"issue":"2","key":"835_CR84","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ccell.2014.11.017","volume":"27","author":"H Wang","year":"2015","unstructured":"Wang H, Yu C, Gao X, Welte T, Muscarella AM, Tian L, et al. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 2015;27(2):193\u2013210. https:\/\/doi.org\/10.1016\/j.ccell.2014.11.017.","journal-title":"Cancer Cell"},{"issue":"1","key":"835_CR85","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1156","volume":"3","author":"V Mayhew","year":"2020","unstructured":"Mayhew V, Omokehinde T, Johnson RW. Tumor dormancy in bone. Cancer Rep (Hoboken). 2020;3(1):e1156. https:\/\/doi.org\/10.1002\/cnr2.1156.","journal-title":"Cancer Rep (Hoboken)"},{"issue":"4","key":"835_CR86","doi-asserted-by":"publisher","first-page":"480","DOI":"10.18632\/oncotarget.27439","volume":"11","author":"A Gnoni","year":"2020","unstructured":"Gnoni A, Brunetti O, Longo V, Calabrese A, Argentiero AL, Calbi R, et al. Immune system and bone microenvironment: rationale for targeted cancer therapies. Oncotarget. 2020;11(4):480\u20137. https:\/\/doi.org\/10.18632\/oncotarget.27439.","journal-title":"Oncotarget"},{"issue":"12","key":"835_CR87","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1200\/JCO.2013.51.3572","volume":"34","author":"MJ Smyth","year":"2016","unstructured":"Smyth MJ, Yagita H, McArthur GA. Combination anti-CTLA-4 and anti-RANKL in metastatic melanoma. J Clin Oncol. 2016;34(12):e104\u20136. https:\/\/doi.org\/10.1200\/JCO.2013.51.3572.","journal-title":"J Clin Oncol"},{"issue":"19","key":"835_CR88","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.1158\/1078-0432.CCR-17-0606","volume":"23","author":"E Ahern","year":"2017","unstructured":"Ahern E, et al. Co-administration of RANKL and CTLA4 antibodies enhances lymphocytemediated anti-tumor immunity in mice. Clin Cancer Res. 2017;23(19):5789\u2013801. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0606.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"835_CR89","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1359\/JBMR.040305","volume":"19","author":"PJ Bekker","year":"2004","unstructured":"Bekker PJ, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19(7):1059\u201366. https:\/\/doi.org\/10.1359\/JBMR.040305.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"835_CR90","doi-asserted-by":"publisher","first-page":"96","DOI":"10.14310\/horm.2002.1226","volume":"8","author":"PD Papapetrou","year":"2009","unstructured":"Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens). 2009;8(2):96\u2013110. https:\/\/doi.org\/10.14310\/horm.2002.1226.","journal-title":"Hormones (Athens)"},{"issue":"335","key":"835_CR91","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","volume":"1996","author":"PC de Groen","year":"1996","unstructured":"de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;1996(335):1016\u201321.","journal-title":"N Engl J Med"},{"issue":"6","key":"835_CR92","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s00198-017-3992-5","volume":"28","author":"AW Popp","year":"2017","unstructured":"Popp AW, Senn R, Curkovic I, Senn C, Buffat H, Popp PF, et al. Factors associated with acutephase response of bisphosphonate-na\u00efve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate. Osteoporos Int. 2017;28(6):1995\u20132002. https:\/\/doi.org\/10.1007\/s00198-017-3992-5.","journal-title":"Osteoporos Int"},{"key":"835_CR93","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/DHPS.S7727","volume":"3","author":"EM Lewiecki","year":"2011","unstructured":"Lewiecki EM. Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis. Drug Healthc Patient Saf. 2011;3:79\u201391. https:\/\/doi.org\/10.2147\/DHPS.S7727.","journal-title":"Drug Healthc Patient Saf"},{"issue":"8","key":"835_CR94","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756\u201365. https:\/\/doi.org\/10.1056\/NEJMoa0809493.","journal-title":"N Engl J Med"},{"issue":"2","key":"835_CR95","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.oooo.2018.09.008","volume":"127","author":"O Nicolatou-Galitis","year":"2019","unstructured":"Nicolatou-Galitis O, Schi\u00f8dt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;127(2):117\u201335. https:\/\/doi.org\/10.1016\/j.oooo.2018.09.008.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"5","key":"835_CR96","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3238\/arztebl.2017.0063","volume":"114","author":"P Poxleitner","year":"2017","unstructured":"Poxleitner P, Engelhardt M, Schmelzeisen R, Voss P. The prevention of medication-related osteonecrosis of the jaw. Dtsch Arztebl Int. 2017;114(5):63\u20139. https:\/\/doi.org\/10.3238\/arztebl.2017.0063.","journal-title":"Dtsch Arztebl Int"},{"issue":"10","key":"835_CR97","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014;72(10):1938\u201356. https:\/\/doi.org\/10.1016\/j.joms.2014.04.031.","journal-title":"J Oral Maxillofac Surg"},{"issue":"3","key":"835_CR98","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/annonc\/mdv617","volume":"27","author":"P Hadji","year":"2016","unstructured":"Hadji P, Coleman RE, Wilson C, Powles TJ, Cl\u00e9zardin PA, Costa M, et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European panel. Ann Oncol. 2016;27(3):379\u201390. https:\/\/doi.org\/10.1093\/annonc\/mdv617.","journal-title":"Ann Oncol"},{"issue":"20","key":"835_CR99","doi-asserted-by":"publisher","first-page":"39995","DOI":"10.1016\/j.annonc.2020.07.019","volume":"S0923-7534","author":"R Coleman","year":"2020","unstructured":"\u2022Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, et al. Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol. 2020;S0923-7534(20):39995\u20136. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.019. European guidelines on proper management of bone loss in cancer patients.","journal-title":"Ann Oncol"},{"issue":"18","key":"835_CR100","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1200\/JCO.2016.70.7257","volume":"35","author":"S Dhesy-Thind","year":"2017","unstructured":"Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a cancer care Ontario and American society of clinical oncology clinical practice guideline. J Clin Oncol. 2017;35(18):2062\u201381. https:\/\/doi.org\/10.1200\/JCO.2016.70.7257.","journal-title":"J Clin Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00835-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-021-00835-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00835-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T21:29:53Z","timestamp":1618954193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-021-00835-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,16]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["835"],"URL":"https:\/\/doi.org\/10.1007\/s11864-021-00835-2","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,16]]},"assertion":[{"value":"18 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anna Diana has received compensation from Roche, Doxopharma and Springer Healthcare for service as a consultant, and has received reimbursement for travel and accommodations from Roche, Istituto Gentili, Italfarmaco, Ipsen and Novartis.Francesca Carlino has received reimbursement for travel and accommodations from Italfarmaco.Emilio Francesco Giunta declares that he has no conflict of interest.Elisena Franzese declares that she has no conflict of interest.Luigi Pio Guerrera declares that he has no conflict of interest.Vincenzo Di Lauro declares that he has no conflict of interest.Fortunato Ciardiello declares that he has no conflict of interest.Bruno Daniele has received compensation from Ipsen, Eisai, Eli Lilly, AstraZeneca, Sanofi, MSD, Bayer, Roche and Amgen for service as a consultant, and he has received non-financial support from Ipsen, Sanofi and Bayer.Michele Orditura has received research funding from Genentech, Pfizer, Eisai and Novartis; has received compensation from Italfarmaco, Epionpharma, Eli Lilly, Tesaro, Genentech and MSD for service as a consultant\/advisor; and has received reimbursement for travel and accommodations from Roche and Eisai.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"45"}}